Department of Clinical Medicine, University of Bergen, Bergen, Norway;
Department of Surgery, Haukeland University Hospital, Bergen, Norway.
Cancer Genomics Proteomics. 2022 Mar-Apr;19(2):130-144. doi: 10.21873/cgp.20309.
BACKGROUND/AIM: Better stratification of the risk of relapse will help select the right patients for adjuvant treatment and improve targeted therapies for patients with colon cancer.
To understand why a subset of tumors relapse, we compared the proteome of two groups of patients with colon cancer with similar stage, stratified based on the presence or absence of recurrence.
Using tumor biopsies from the primary operation, we identified dissimilarity between recurrent and nonrecurrent mismatch satellite stable colon cancer and found that signaling related to immune activation and inflammation was associated with relapse.
Immune modulation may have an effect on mismatch satellite stable colon cancer. At present, immune therapy is offered primarily to microsatellite instable colon cancer. Hopefully, immune therapy in mismatch satellite stable colon cancer beyond PD-1 and PD-L1 inhibitors can be implemented.
背景/目的：更好地对复发风险进行分层，将有助于为辅助治疗选择合适的患者，并为结肠癌患者提供靶向治疗。
为了了解为什么一部分肿瘤会复发，我们比较了两组具有相似分期的结肠癌患者的蛋白质组学，这些患者根据是否存在复发进行了分层。
使用原发性手术中的肿瘤活检，我们发现复发和非复发错配卫星稳定结肠癌之间存在差异，并且发现与免疫激活和炎症相关的信号与复发有关。
免疫调节可能对错配卫星稳定结肠癌有影响。目前，免疫疗法主要用于微卫星不稳定结肠癌。希望可以在错配卫星稳定结肠癌中实施 PD-1 和 PD-L1 抑制剂以外的免疫治疗。
